News Dry eye disease: OPUS-3 phase 3 trial with lifitegrast meets primary and key secondary endpoints by Medical News Today • 2015/10/28 • 0 Comments Shire plc has announced positive topline results from OPUS-3, a phase 3 efficacy and safety study of lifitegrast versus placebo.